Tempest Therapeutics (FRA:3OS0) OCF Margin %: 0.00% (As of Mar. 2026)


FRA:3OS0 Tempest Therapeutics Inc FRA:3OS0
32 GF Score
Price €5.82
! 1 Warning Sign
View Full Analysis

What is Tempest Therapeutics OCF Margin %?

Tempest Therapeutics FRA:3OS0 32 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates FRA:3OS0 with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 956 Biotechnology companies, Tempest Therapeutics ranks worse than 104602.41% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Tempest Therapeutics's Cash Flow from Operations for the three months ended in Mar. 2026 was €-6.57 Mil. Tempest Therapeutics's Revenue for the three months ended in Mar. 2026 was €0.00 Mil. Therefore, Tempest Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Tempest Therapeutics's current OCF Yield % is -148.74%.

The historical rank and industry rank for Tempest Therapeutics's OCF Margin % or its related term are showing as below:


FRA:3OS0's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -68.59
* Ranked among companies with meaningful OCF Margin % only.

Tempest Therapeutics OCF Margin % Related Terms

Tempest Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Tempest Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tempest Therapeutics OCF Margin % Chart

Tempest Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Tempest Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:3OS0
32GF Score
Tempest Therapeutics Inc FRA:3OS0
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tempest Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Tempest Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-22.904/0
= %

Tempest Therapeutics's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-6.572/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Tempest Therapeutics (FRA:3OS0) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Tempest Therapeutics and its competitors. According to the industry distribution chart, Tempest Therapeutics ranks #999999 out of 956 companies in the Biotechnology industry.
Is Tempest Therapeutics' OCF Margin % too high?
Tempest Therapeutics' current OCF Margin % is 0.00%. Based on the distribution chart, Tempest Therapeutics ranks #999999 out of 956 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Tempest Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Tempest Therapeutics' OCF Margin % compare to HOWL and INTI?
According to the Biotechnology industry distribution chart, Tempest Therapeutics ranks #999999 out of 956 companies for OCF Margin %. This places Tempest Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Tempest Therapeutics and its competitors. Tempest Therapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tempest Therapeutics stock overvalued right now?
Tempest Therapeutics (FRA:3OS0) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Tempest Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Tempest Therapeutics (FRA:3OS0), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tempest Therapeutics Business Description

Other Exchanges TPST:USA
Address 2000 Sierra Point Parkway, Suite 400, Brisbane, CA, USA, 94005
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
32GF Score

Get the complete analysis for FRA:3OS0

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.82
Price